1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in Belgium, MarketLine

Generics in Belgium, MarketLine

  • December 2014
  • -
  • MarketLine
  • -
  • 33 pages

Introduction

Generics in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2010-14, and forecast to 2019). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

*The Belgian generics market is expected to generate total revenues of $596.6m in 2014, representing a compound annual growth rate (CAGR) of 4.4% between 2010 and 2014.

*Market consumption volume is forecast to increase with a CAGR of 4.5% between 2010 and 2014, to reach a total of 27.9% of total pharma volume in 2014.

*The performance of the market is forecast to decelerate, with an anticipated CAGR of 3% for the five-year period 2014 - 2019, which is expected to drive the market to a value of $690.7m by the end of 2019.

Features

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Belgium

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Belgium

Leading company profiles reveal details of key generics market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Belgium generics market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Belgium economy

Key Questions Answered

What was the size of the Belgium generics market by value in 2014?

What will be the size of the Belgium generics market in 2019?

What factors are affecting the strength of competition in the Belgium generics market?

How has the market performed over the last five years?

Table Of Contents

Generics in Belgium, MarketLine
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Mylan Inc. 19
Sandoz International GmbH 22
Sanofi SA 23
Teva Pharmaceutical Industries Limited 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related MarketLine research 32

LIST OF TABLES
Table 1: Belgium generics market value: $ million, 2010-14(e) 8
Table 2: Belgium generics market volume: % of total pharma volume, 2010-14(e) 9
Table 3: Belgium generics market geography segmentation: $ million, 2014(e) 10
Table 4: Belgium generics market value forecast: $ million, 2014-19 11
Table 5: Belgium generics market volume forecast: % of total pharma volume, 2014-19 12
Table 6: Mylan Inc.: key facts 19
Table 7: Mylan Inc.: key financials ($) 20
Table 8: Mylan Inc.: key financial ratios 20
Table 9: Sandoz International GmbH: key facts 22
Table 10: Sanofi SA: key facts 23
Table 11: Sanofi SA: key financials ($) 24
Table 12: Sanofi SA: key financials (€) 24
Table 13: Sanofi SA: key financial ratios 24
Table 14: Teva Pharmaceutical Industries Limited: key facts 26
Table 15: Teva Pharmaceutical Industries Limited: key financials ($) 27
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios 27
Table 17: Belgium size of population (million), 2010-14 29
Table 18: Belgium gdp (constant 2005 prices, $ billion), 2010-14 29
Table 19: Belgium gdp (current prices, $ billion), 2010-14 29
Table 20: Belgium inflation, 2010-14 30
Table 21: Belgium consumer price index (absolute), 2010-14 30
Table 22: Belgium exchange rate, 2010-14 30

LIST OF FIGURES
Figure 1: Belgium generics market value: $ million, 2010-14(e) 8
Figure 2: Belgium generics market volume: % of total pharma volume, 2010-14(e) 9
Figure 3: Belgium generics market geography segmentation: % share, by value, 2014(e) 10
Figure 4: Belgium generics market value forecast: $ million, 2014-19 11
Figure 5: Belgium generics market volume forecast: % of total pharma volume, 2014-19 12
Figure 6: Forces driving competition in the generics market in Belgium, 2014 13
Figure 7: Drivers of buyer power in the generics market in Belgium, 2014 14
Figure 8: Drivers of supplier power in the generics market in Belgium, 2014 15
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Belgium, 2014 16
Figure 10: Factors influencing the threat of substitutes in the generics market in Belgium, 2014 17
Figure 11: Drivers of degree of rivalry in the generics market in Belgium, 2014 18
Figure 12: Mylan Inc.: revenues and profitability 20
Figure 13: Mylan Inc.: assets and liabilities 21
Figure 14: Sanofi SA: revenues and profitability 25
Figure 15: Sanofi SA: assets and liabilities 25
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability 27
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.